Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron for Pain Motivated Urinary Frequency and Urgency
NCT02981459Phase 4Withdrawn
- Sponsor
- University at Buffalo
- Start
- Dec 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mirabegron in bladder pain syndrome (BPS), sponsored by University at Buffalo. Primary endpoint: Number of pain motivated voids per 24 hours at 12 weeks. Planned start Dec 2017; status: withdrawn.
02
Drugs
mirabegron
03
Conditions
bladder pain syndrome (BPS)
Beyond the preview
Go deeper on NCT02981459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981459.